Open Access

Dendritic cells loaded with CD44+ CT‑26 colon cell lysate evoke potent antitumor immune responses

  • Authors:
    • Changhao Fu
    • Ning Zhou
    • Yuanyuan Zhao
    • Jinyue Duan
    • Hao Xu
    • Yi Wang
  • View Affiliations

  • Published online on: October 2, 2019     https://doi.org/10.3892/ol.2019.10952
  • Pages: 5897-5904
  • Copyright: © Fu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Increasing evidence supports the concept that cancer stem cells (CSCs) are responsible for cancer progression and metastasis, therapy resistance and relapse. In addition to conventional therapies for colon cancer, the development of immunotherapies targeting cancer stem cells appears to be a promising strategy to suppress tumor recurrence and metastasis. In the present study, dendritic cells (DCs) were pulsed with whole‑tumor cell lysates or total RNA of CD44+ colon cancer stem cells (CCSCs) isolated from mouse colon adenocarcinoma CT‑26 cell cultures and investigated for their antitumor immunity against CCSCs in vivo and in vitro. In a model of colon adenocarcinoma using BALB/c mice, a sequential reduction in tumor volume and weight was associated with an extended survival in tumor‑bearing mice vaccinated with DCs pulsed with RNA or CCSC lysate. In addition, a lactate dehydrogenase assay indicated that cytotoxic T‑cells derived from the treated mice exhibited strong cytotoxic activity. Additionally, an enzyme‑linked immunosorbent assay revealed that the cytotoxic T‑cells of the treated mice released higher levels of interferon‑γ against CCSCs compared with those of the control group. In all experiments, the antitumor efficacy of the lysate‑pulsed DC‑treated and RNA‑pulsed DC‑treated groups were significantly higher compared with that of the DC‑treated and control groups. The results of the present study indicated the potential use of DCs pulsed with cancer stem cell lysates as a potent therapeutic antigen to target CSCs in colon cancer. Additionally, the results provided a rationale for using lysate‑pulsed DCs in vivo to eliminate residual tumor deposits in post‑operative patients.

Related Articles

Journal Cover

December 2019
Volume 18 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Fu, C., Zhou, N., Zhao, Y., Duan, J., Xu, H., & Wang, Y. (2019). Dendritic cells loaded with CD44+ CT‑26 colon cell lysate evoke potent antitumor immune responses. Oncology Letters, 18, 5897-5904. https://doi.org/10.3892/ol.2019.10952
MLA
Fu, C., Zhou, N., Zhao, Y., Duan, J., Xu, H., Wang, Y."Dendritic cells loaded with CD44+ CT‑26 colon cell lysate evoke potent antitumor immune responses". Oncology Letters 18.6 (2019): 5897-5904.
Chicago
Fu, C., Zhou, N., Zhao, Y., Duan, J., Xu, H., Wang, Y."Dendritic cells loaded with CD44+ CT‑26 colon cell lysate evoke potent antitumor immune responses". Oncology Letters 18, no. 6 (2019): 5897-5904. https://doi.org/10.3892/ol.2019.10952